An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity

Oncologist

Volumn 16, Issue 9, 2011, Pages 1325-1332

  Mir, Olivier ^a,b   Coriat, Romain ^a   Cabanes, Laure ^a   Ropert, Stanislas ^a   Billemont, Bertrand ^a   Alexandre, Jérôme ^a   Durand, Jean Philippe ^a   Treluyer, Jean Marc ^b   Knebelmann, Bertrand ^c   Goldwasser, Francois ^a  

^a AP HP Paris Descartes University ^*  (France)

^b INSERM   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; FLUOROURACIL;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD PRESSURE MONITORING; CANCER PATIENT; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED DISEASE; FEMALE; HUMAN; HYPERTENSION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OBSERVATIONAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD PRESSURE DETERMINATION; BLOOD PRESSURE MONITORING, AMBULATORY; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS;

EID: 80053200932     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0002     Document Type: Article

References (21)

1. Izzedine H, Ederhy S, Goldwasser F et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 2009;20:807-815.
2. Zhu X, Wu S, Dahut WL et al. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: Systematic review and meta-analysis. Am J Kidney Dis 2007;49:186-193.
3. Scappaticci FA, Skillings JR, Holden SN et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007;99:1232-1239.
4. Mir O, Ropert S, Alexandre J et al. Hypertension as a surrogate marker for the activity of anti-VEGF agents [letter]. Ann Oncol 2009;20:967-970.
5. Trotti A, Colevas AD, Setser A et al. CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Se-min Radiat Oncol 2003;13:176-181.
6. Azizi M, Chedid A, Oudard S. Home blood-pressure monitoring in patients receiving sunitinib. N Engl J Med 2008;358:95-97.
7. Bamias A, Lainakis G, Manios E et al. Could rigorous diagnosis and management of hypertension reduce cardiac events in patients with renal cell carcinoma treated with tyrosine kinase inhibitors? [letter] J Clin Oncol 2009;27:2567-2569; author reply 2569-2570.
8. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinote-can, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
9. Cifkova R, Erdine S, Fagard R et al. Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. J Hypertens 2003;21: 1779-1786.
10. Miller AB, Hoogstraten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1981;47:207-214.
11. Lowery M, Power D, Behbehani A et al. Hypertension is a significant adverse effect of bevacizumab treatment. ASCO Meeting Abstracts 2007;25: 14134.
12. Grothey A, Sugrue MM, Purdie DM et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: Results from a large observational cohort study (BRiTE). J Clin Oncol 2008;26:5326-5334.
13. Schneider BP, Wang M, Radovich M et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008;26:4672-4678.
14. Scartozzi M, Galizia E, Chiorrini S et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 2009;20:227-230.
15. Friberg G, Kasza K, Vokes EE et al. Early hypertension as a potential pharmacodynamic marker for survival in pancreatic cancer patients treated with bevacizumab and gemcitabine. ASCO Meeting Abstracts 2005;23:3020.
16. Rini B, Schiller JH, Fruehauf JP et al. Association of diastolic blood pressure >90 mmHg with overall survival in patients treated with axitinib (AG-013736). ASCO Meeting Abstracts 2008;26:3543.
17. Rixe O, Billemont B, Izzedine H. Hypertension as a predictive factor of sunitinib activity [letter]. Ann Oncol 2007;18:1117.
18. Spano JP, Chodkiewicz C, Maurel J et al. Efficacy of gemcitabine plus ax-itinib compared with gemcitabine alone in patients with advanced pancreatic cancer: An open-label randomised phase II study. Lancet 2008;371: 2101-2108.
19. Rixe O, Dutcher J, Motzer R et al. Diastolic blood pressure (dBP) and phar-macokinetics (PK) as predictors of axitinib efficacy in metastatic renal cell cancer (mRCC). ASCO Meeting Abstracts 2009;27:5045.
20. Maitland ML, Kasza KE, Karrison T et al. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res 2009;15:6250-6257.
21. Maitland M, Moshier K, Imperial J et al. Blood pressure as a biomarker for sorafenib, an inhibitor of the vascular endothelial growth factor (VEGF) signaling pathway. ASCO Meeting Abstracts 2006;24:2035.